XML 42 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
3 Months Ended
Mar. 31, 2025
Segment Reporting [Abstract]  
Schedule of Segment Reporting Information, by Segment
Detailed information regarding the Company's single operating segment's revenues, expenses and operating loss are as follows:
Three Months Ended March 31,
20252024
Revenue from collaborative arrangements $65,343 $— 
Less:
Research and development:
     INO-31073,507,342 7,645,664 
     INO-3112 and other Immuno-oncology1,315,084 2,020,750 
     Other programs (a)107,425 623,666 
     Engineering and device-related5,061,810 3,751,261 
     Stock-based compensation553,394 1,060,487 
     Other unallocated expenses 5,545,847 5,811,962 
General and administrative9,024,970 10,571,179 
Total operating expenses25,115,872 31,484,969 
Interest income808,077 1,500,290 
Interest expense— (177,833)
Change in fair value of common stock warrant liability3,712,872 — 
Gain (loss) on investment in affiliated entity695,131 (126,018)
Net unrealized gain on available-for-sale equity securities140,234 500,877 
Other expense, net(482)(682,218)
Net loss$(19,694,697)$(30,469,871)

(a) Net of contributions received from grant agreements and recorded as contra-research and development expense.